Clinical Trial Update: Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating how well Zongertinib is tolerated when given in combination with chemotherapy with or without pembrolizumab in advanced non-sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Zongertinib (Zongertinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Cancer, Non-squamous, Non-small Cell | Phase 2 | Status: NOT_YET_RECRUITING